Podcasts about sandoz

Die beiden Experten für das Börsengeschehen haben vier Aktien mitgebracht, die von dem jüngst beschlossenen großen Koalitionsvertrag der neuen deutschen Regierung profitieren könnten: Der IT-Dienstleister Cancom: für 2025 hoffen Anleger auf eine Erholung, insbesondere durch die Integration mehrerer Übernahmen. Eine Bodenbildung zeigt sich, und damit einher könnte eine Stabilisierung gar schon erfolgt sein. Die IT liegt in Deutschland noch am Boden, doch mit einem Standbein im öffentlichen Sektor könnte Cancom einen Teil des als "Sondervermögen" deklarierten Investitionsbetrages erlangen bzw. damit entsprechende Projekte umsetzen. Die PNE AG, spezialisiert auf Wind- und Solarenergieprojekte, verzeichnete 2024 ein starkes Wachstum mit einem EBITDA-Anstieg von 73 Prozent auf 69 Mio. Euro. Für 2025 wird ein weiterer Anstieg auf bis zu 110 Mio. Euro erwartet. Seit dem Tief vom Jahreswechsel befindet sich der Kurs wieder deutlich am Steigen. Hier zeigt sich: die Richtung stimmt wieder für den Anleger. Hypoport, ein Finanzdienstleister im Bereich Immobilienfinanzierung prognostiziert für 2025 einen Umsatzanstieg auf mindestens 640 Mio. Euro sowie ein EBIT zwischen 30 und 36 Mio. Euro. Die Aktie hat sich seit Jahresbeginn um über 20 Prozent erholt, nachdem sie zuvor eine Korrektur erfahren hatte. Jedoch benötigt das Wertpapier noch einen weiteren Anstieg, um auch hier eine Bodenbildung sicherer zu prognostizieren. Das Biotechnologie-Unternehmen Evotec steht vor Herausforderungen: Für 2024 wurde die Umsatzprognose auf 790–820 Mio. Euro gesenkt, und das bereinigte EBITDA soll zwischen 15 und 35 Mio. Euro liegen, was einem deutlichen Rückgang entspricht. Gründe sind unter anderem langsame Auftragstransformation und hoher Margendruck. Trotzdem setzt Evotec auf strategische Partnerschaften, etwa mit Bristol Myers Squibb und Sandoz, um langfristiges Wachstum zu sichern. Die Aktie steht derzeit im Abwärtstrend, und man braucht einen langen Atem, um die Resultate aus den Plänen des Vorstands für die Jahre 2027 und 2028 zu sehen. Mit Blick auf weitere Quartalszahlen und die Termine des Tages haben Sie einen umfassenden Blick auf den heutigen Handelstag. Kommen Sie bestens informiert mit TRADERS´ media GmbH und der LS Exchange durch den Handelstag.

This Day in Legal History: President Lincoln DiesOn this day in legal history, April 15, 1865, President Abraham Lincoln died from a gunshot wound inflicted the night before by actor and Confederate sympathizer John Wilkes Booth. The assassination occurred at Ford's Theatre in Washington, D.C., where Lincoln was watching a play with his wife. He was shot in the back of the head and never regained consciousness, dying the next morning at 7:22 a.m. His death was the first assassination of a U.S. president and triggered a constitutional transition of power during a critical moment in American history. Vice President Andrew Johnson was sworn in the same day, inheriting the enormous task of leading the country through the fragile early stages of Reconstruction.Legally, Lincoln's assassination set several precedents. It led to the use of military tribunals to try civilians involved in Booth's conspiracy, a decision that remains controversial in constitutional law. The event also underscored the importance of presidential succession, later clarified by the 25th Amendment. In the immediate aftermath, martial law and curfews were imposed in the capital, and a massive manhunt ensued for Booth and his co-conspirators. The killing intensified public sentiment against the South and complicated efforts to reunify the nation. Johnson's approach to Reconstruction diverged sharply from Lincoln's more conciliatory plans, shaping decades of legal and political conflict over civil rights. The assassination deeply impacted how the federal government approached both national security and executive protection. The tragedy marked not just the loss of a president, but a shift in the legal and political structure of post-Civil War America.As Lincoln's funeral train retraced the route that had carried him from obscurity in Illinois to the presidency, it served as a symbolic farewell to both the man and the future he might have shaped. Each stop along the way—cities draped in mourning, crowds in silent grief—marked not only the end of his political journey but also the shunting off of a potential trajectory for his second term. Had Lincoln lived, his vision for a more lenient and reconciliatory Reconstruction might have softened the bitter divisions that would later deepen under Andrew Johnson's combative leadership. Perhaps civil rights protections would have been implemented sooner, with Lincoln using his political capital and moral authority to push for more lasting equality. The possibility remains that a different course could have been taken—one that prioritized unity without compromising justice, and that may have led to a more inclusive and less violent post-war America.Kilmar Abrego Garcia, a legally residing Salvadoran migrant in Maryland with a U.S. work permit, was wrongly deported to El Salvador in March, despite a judge's order blocking his removal. The Trump administration acknowledged the deportation was in error but has told a federal court it is not obligated to help him return from prison in El Salvador, interpreting a Supreme Court directive to "facilitate" his return as limited to removing domestic barriers—not assisting with his release abroad. A U.S. District Court judge had ordered the government to bring him back, a decision the Supreme Court upheld by rejecting the administration's appeal. However, a top immigration official has now argued the deportation order is moot, citing Abrego Garcia's alleged ties to MS-13, a group newly designated as a foreign terrorist organization. The State Department has confirmed that Abrego Garcia is "alive and secure" in a terrorism detention facility in El Salvador. Legal efforts continue, with Abrego Garcia's attorneys seeking more information from the government. The administration warns this could disrupt diplomatic talks, particularly with El Salvador's President Nayib Bukele visiting Washington. President Trump has said his administration would comply if ordered directly by the Supreme Court.Trump administration says it is not required to help wrongly deported man return to US | ReutersSandoz, a Swiss generic drugmaker, has filed a U.S. antitrust lawsuit against Amgen, accusing it of unlawfully maintaining a monopoly on its arthritis drug Enbrel. The lawsuit, filed in federal court in Norfolk, Virginia, alleges that Amgen created a "thicket of patents" to block the entry of biosimilar competitors like Sandoz's Erelzi, which has been approved by the FDA since 2016 but has not launched in the U.S. Sandoz claims this strategy has kept its lower-cost alternative off the market, depriving patients of affordable options and causing the company to lose millions in potential monthly sales. Amgen has not yet commented on the lawsuit. Enbrel generated $3.3 billion in U.S. revenue in 2024 alone and is used to treat inflammatory diseases such as rheumatoid arthritis. Sandoz argues that Amgen's patent practices violate federal antitrust laws by suppressing competition and artificially extending its market dominance. The company is seeking an injunction to stop Amgen from using its patent portfolio in this way, as well as financial damages for lost sales.Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug | ReutersThe U.S. Government Accountability Office (GAO) has agreed to investigate recent changes at the Securities and Exchange Commission (SEC), including those influenced by the White House and the Department of Government Efficiency (DGE), led by Elon Musk. This probe follows a request from Senators Elizabeth Warren and Mark Warner, who raised concerns about the SEC's ability to fulfill its regulatory duties amid sweeping restructuring efforts. Since President Trump's return to office and the Republican takeover of the agency, the SEC has reduced staff, ended leases, and reorganized operations. It has also scaled back enforcement efforts and seen a wave of resignations as part of a broader federal downsizing initiative. The GAO confirmed that the request for an investigation falls within its authority, with the review expected to begin in about three months. Lawmakers stress the importance of understanding how these changes may be undermining the SEC's mission. The agency's funding, while approved by Congress, is sourced from transaction fees rather than taxpayer dollars. These developments coincide with market instability triggered by Trump's recent tariff announcement.US congressional watchdog to probe changes at the SEC, letter says | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes New York Times bestselling author Norman Ohler. Find full show notes and links here: https://thethirdwave.co/podcast/episode-297/?ref=278 Norman shares his deep research into the hidden history of LSD, revealing the untold connections between Arthur Stoll (CEO of Sandoz), Nazi Germany, and the CIA's MKUltra program. He explains how LSD's development as a mental health medicine was derailed by intelligence agencies seeking a "truth drug" for interrogations, and how the substance traveled from Swiss laboratories to Nazi concentration camps and eventually to American universities. Norman also discusses his personal connection to psychedelics through his mother's Alzheimer's treatment with microdosing, and offers thoughtful reflections on the current psychedelic renaissance. Norman Ohler is one of Germany's best living writers: a New York Times Bestselling author, translated into over 30 languages. His books include "Blitzed", "The Bohemians", and "Tripped". He has 2 children and lives in Berlin. Highlights: Welcome & introduction Who is Arthur Stoll, the grandfather of psychedelics? The Nazi Germany and LSD connection Albert Hoffman's complicated relationship with LSD The pharmaceutical politics behind psychedelic suppression Reflections on the modern psychedelic renaissance The challenges of psychedelics in a globalized society From "Blitzed" to "Tripped": Norman's research journey Norman's personal connection: Microdosing for Alzheimer's The mysterious story of JFK and LSD Episode Links: Website Instagram: @normanohler Norman's book "Tripped: Nazi Germany, the CIA and the Dawn of the Psychedelic Age" Norman's previous book "Blitzed: Drugs in the Third Reich" Rise and Fall of the Third Reich" by William Shirer These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

Il y a 80 ans, le chimiste Albert Hofmann enfourchait son vélo pour une folle cavalcade à travers Bâle, imprégné volontairement et surpris par la substance qu'il était parvenu à synthétiser quelques années plus tôt : le LSD. Il était alors loin de se douter que cette drogue psychédélique, capable de soulager certaines maladies psychiques, allait devenir, avec l'aide d'anciens chimistes nazis, un objet de recherche militaire et un outil de contrôle mental utilisé par la CIA pendant la Guerre froide. Loin également d'imaginer que le LSD allait non pas déferler sur le marché du médicament grâce à sa firme Sandoz, mais accéder à la notoriété grâce au mouvement psychédélique et aux milieux artistiques et intellectuels des années 60. En 1966, il est interdit et retombe finalement dans la clandestinité. Aujourd'hui la recherche montre un intérêt renouvelé pour le potentiel thérapeutique des substances psychédéliques comme le LSD. Daniele Zullino est psychiatre et médecin chef du service d'addictologie des Hôpitaux universitaires de Genève, il est au micro de Céline Roduit pour Histoire Vivante.

US futures gained after the Wall St. close as Lutnick suggested Trump could potentially reduce tariffs on Canada and Mexico, perhaps as soon as Wednesday.APAC mixed but with strength in China after data and the Official Growth Report which maintained a growth target of around 5% and pledged measures to boost spending.EUR underpinned by German debt brake reform with the DXY under pressure as a result, Cable hit a YTD peak while NZD was unreactive to Orr resigning.Bunds weighed on by CDU's Merz saying the first results on debt brake reform have been reached with the SPD alongside proposing new instruments and defence exemptions.Fed's Williams said he does not see the need to change policy currently, and described it as "still restrictive" and with the right balance; highlighted UoM inflation data as one to watch.Crude subdued, XAU range bound and Copper gained on China's report; Trump said he received a letter from Zelensky who is ready to come back to the table.Looking ahead, highlights include Swiss CPI, US ADP National Employment, US Factory Orders, ISM Services, China NPC, Fed's Beige Book, BoE Treasury Select Hearing, Speakers including BoE's Bailey, Pill, Taylor and Greene, Supply from UK, Earnings from Telecom Italia, Bayer, Adidas, Sandoz, Abercrombie & Fitch, Foot Locker & Marvell.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

“You don't just need to be good; you need to be better than others to drive your business,” warns Olaf Birkenmeier, Head of External Manufacturing at Polpharma Biologics, describing the evolutionary pressure facing Western biopharmaceutical manufacturers.Olaf Birkenmeier leads external manufacturing at Polpharma Biologics, bringing senior leadership experience from Sandoz and Novartis to bear on the challenges facing by pharma companies in an increasingly competitive global market.In a recent PharmaSource podcast interview, Olaf draws parallels between the pharmaceutical industry's competitive landscape and the Red Queen hypothesis – an evolutionary biology theory proposed in 1973 that suggests species must constantly adapt, evolve, and proliferate to survive while pitted against ever-evolving opposing species. This principle, he argues, perfectly captures the continuous innovation and improvement required for Western biopharmaceutical companies to maintain their market position.Join Olaf Birkenmeier at ⁠CDMO Live 2025⁠Read the full article on PharmaSource

durée : 00:27:23 - Les Midis de Culture - par : Marie Sorbier - Au programme du débat critique, du spectacle vivant pour tous les âges : "R.O.B.I.N." de Maïa Sandoz et "Yongoyely" du Circus Baobab. - réalisation : Laurence Malonda - invités : Lucile Commeaux Critique et chroniqueuse du "Regard culturel" à la matinale de France Culture ; Zoé Sfez Productrice de La Série musicale sur France Culture

Comment les rhumatologues peuvent-ils gérer la prescription d'un vaccin en tenant compte des traitements immunosuppresseurs ? Quel est le délai recommandé pour vacciner un patient ayant récemment contracté une infection, et pourquoi ? Quels sont les conseils pour motiver les patients qui hésitent ou ont des inquiétudes face aux vaccins ? Comment adapter les recommandations vaccinales en fonction des spécificités des patients en rhumatologie ? Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

Quelles sont les raisons principales pour lesquelles les rhumatologues doivent s'intéresser à la vaccination ? Quels sont les nouveaux vaccins susceptibles d'avoir un impact sur les patients suivis en rhumatologie ? Quelles avancées récentes marquent l'actualité dans le domaine des vaccinations ?  Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

Die Verpackung eines Sandoz-Generikums gibt zu reden. Die Blister sind riesig – gerade im Vergleich zum Originalmedikament. Warum so viel Abfall für so wenig Tabletten? +++ Weiteres Thema: Wieso gibt es in Coop und Migros keine Altersprüfung beim Verkauf von Kirschstengeli?

Hannah Sandoz creates expansive ambient atmospheres in Studio A using only their guitar and voice.

Psykedeliska droger är på uppsving och ses av vissa som rena mirakelmedicinen mot diverse psykiska besvär. Men att beskriva upplevelserna tycks fortfarande utom räckhåll, konstaterar Fredrik Sjöberg. Lyssna på alla avsnitt i Sveriges Radio Play. ESSÄ: Detta är en text där skribenten reflekterar över ett ämne eller ett verk. Åsikter som uttrycks är skribentens egna. Denna essä sändes första gången i januari 2020. Betänk följande scenario: en grottmänniska från stenåldern förflyttas genom en hypotetisk tidsresa till Centralstationen i Stockholm, säg en fredagseftermiddag. Han står där i vänthallen och förundras. Kanske går han också en sväng på stan i rusningstrafiken, varefter han så teleporteras tillbaka till grottans dunkel, där kamraterna nyfiket inväntar hans reseberättelse. Vad ska han säga? Han saknar ord för nästan allt han upplevt. Rulltrappor, mobiltelefoner, trafikljus, tåg – och flygplan som går in för landning på Bromma. Inget av detta finns varken i berättarens eller åhörarnas föreställningsvärld. Inga ord kan ge rättvisa åt upplevelsen, och att enbart säga något om träden på Klara kyrkogård, som tycktes bekanta, känns lite futtigt. Kanske påstår han sig ha träffat gudar, om så bara i form av barska ordningsvakter i blåa uniformer, men troligare är nog ändå att han ger upp alla försök att berätta och istället hemfaller åt ganska allmänt hållna utrop av typen ”Jävlar, vilken grej!”. Ja, eller motsvarande på stenåldersspråk. Lyssnarna i grottan ser klentroget på varandra medan resenären ler ett inåtvänt leende. Ungefär så kan man gestalta ett återkommande bekymmer för de forskare som studerar effekterna av psykedeliska substanser. LSD och så, ni vet. Försökspersonerna har helt enkelt väldigt svårt att beskriva sina upplevelser. När de väl återvänder från en tripp, ofta i noga kontrollerad laboratoriemiljö, sitter de ändå bara där och flinar och uttalar banaliteter i stil med ”Kärleken är allt!”. Professorerna tar sig för pannan. Lika fullt är denna vetenskap mycket lovande. Under många år låg verksamheten i träda, delvis på goda grunder, men under senare år har denna akademiska öken åter börja blomma. LSD, psilocybin och liknande kemikalier blir allt intressantare för psykologer och medicinare som sysslar med depressioner, tvångssyndrom, ångest och beroendesjukdomar. Nog finns även de gamla flumtomtarna kvar, ofta kännetecknade av större frisyr än förstånd, men på det hela taget är hallucinogenerna på väg tillbaka in i den vetenskapliga värmen. Det var trots allt där alltsammans började. Det var i slutet av 1930-talet; den schweiziske kemisten Albert Hofmann på läkemedelsbolaget Sandoz framställde då ett lysergsyrederivat som gavs beteckningen LSD. Som så ofta hittade man inga praktiska användningsområden, men några år senare blev Hofmann av misstag sin egen försökskanin. Han råkade få i sig en gnutta av ämnet och upplevde historiens första LSD-tripp. Snart producerade Sandoz enorma mängder LSD som, i hopp om kommersiella tillämpningar, distribuerades gratis till universitet över hela världen. Under femtiotalet och in på sextiotalet var forskningen intensiv, och förhoppningen var att de psykedeliska substanserna skulle bli för psykiatrin vad mikroskopet var för biologin och teleskopet för astronomerna. Om drömmarna, som Freud sa, var kungsvägen till det undermedvetna, ansågs behandling med LSD vara något av en motorväg. Vid det laget hade man även återupptäckt psilocybinet, ett svampgift med urgamla anor inom högkulturerna i Mellanamerika. De spanska erövrarna försökte ihärdigt utrota kunskapen om dessa magic mushrooms, antagligen på grund av att giftet från bara några få svampar gav så starka, andliga upplevelser att katolikerna låg i lä, hur mycket rökelse och tingeltangel de än försökte med. Konkurrensen blev kort sagt för hård. Men svamparna dök alltså upp igen och tilldrog sig neurokemisternas intresse. Vetandet om de psykiska sjukdomarnas biokemiska grunder, som senare skulle avkasta moderna antidepressiva läkemedel, utvecklades fort under de här åren, delvis genom dessa experiment. Försökspersonernas erfarenheter var onekligen märkliga; de rapporterade om att jaget liksom löstes upp, om surrealistiska rymdresor och ytterst övertygande känslor av samhörighet. Ofta förekom även synestesi, alltså förmågan att se ljud och höra färger. Konstnärerna var inte sena att haka på, och när sedan psykologiprofessorn vid Harvard, Timothy Leary, introducerade substanserna inom hippiekulturen gick det snabbt utför. John Lennon, Bob Dylan och en hel armé av andra yngre trallgökar gjorde reklam, och när så The Summer of Love randades i San Francisco 1967, hade myndigheterna redan förbjudit all användning. Det får man förstå. För även om varken LSD eller psilocybin var beroendeframkallande så gav de ändå oönskade effekter. Viljan att kriga i Vietnam, till exempel, avtog betänkligt. Den seriösa forskningen pågick ännu en tid, men snart var det stopp även där. Tusentals vetenskapliga rapporter föll i glömska. Först vid millennieskiftet började man gräva upp dem igen, och vad som sedan hände berättas boken Psykedelisk renässans av den amerikanske författaren Michael Pollan. Jämförelsen med Renässansen, då man återupptäckte antikens litterära skatter är välfunnen. Så nu är man på det igen, och eftersom tekniken har gått framåt, liksom forskningen om serotonin och andra signalsubstanser, kan man i dag säga en hel del om vad som faktiskt händer i hjärnan under en psykedelisk tripp, samt även formulera goda hypoteser om hur det kan komma sig att sådana utfärder ibland har gynnsam inverkan på människor som är låsta i ältande och tvångstankar. Till historien hör att Michael Pollan testar själv, och fastän han tar hjälp av erfarna reseledare är sinnesintrycken fortfarande hopplöst svåra att återge, vilket författare som Aldous Huxley och Ernst Jünger insåg redan för längesen. Intressantare är vad vetenskapen har att säga. Vad händer till exempel när man stoppar in en påtänd person i en apparat för magnetröntgen, eller mer korrekt magnetisk resonanstomografi? Hypotesen var att hjärnaktiviteten skulle vara kaotisk och starkt förhöjd, men det visade sig vara tvärtom. Särskilt svag var aktiviteten inom det så kallade standardnätverket, ett för tänkandet centralt nätverk som kan liknas vid en orkesterdirigent, vars uppgift är att hålla samman systemet och dämpa hjärnans mer bångstyriga tendenser. Beskrivningarna av jagupplösning, och känslor av samhörighet med allt och alla, tycks ha att göra med denna inaktivering av standardnätverket. Som om personens ego stängdes av. Denna inre dirigent finns för övrigt inte från början; små barn antas därför befinna sig på en psykedelisk tripp för jämnan, vilket väl ungefär alla föräldrar någon gång har anat. Hjärnan kan jämföras vid en dator; när den hänger sig behövs en omstart. Så förklaras varför LSD och annat i den vägen kan bryta behandlingsresistenta depressioner och tvångsmässiga missbruk samt, fascinerande nog, även döende människors ångest. Entusiasterna påminner visserligen om hälsofanatiker som har sett ljuset i form av LCHF eller vad det nu kan vara, så man bör nog inte helt byta ut kantarellerna mot slätskivlingar i släktet Psilocybe, men ändå; andra illegala droger – opiater, amfetamin och så vidare – förekommer lika ofta som läkemedel. Så varför inte också psykedeliska substanser? Om inte annat kan sådana kemiska äventyr säkerligen ersätta en del av de resor som ändå inte ger mycket mer än flygskam, tarmparasiter och foton av elefanter som ingen vill se. Fredrik Sjöberg, författare och biolog Litteratur Michel Pollan: Psykedelisk renässans – den nya vetenskapen om medvetandet, döden, beroende, depression och transcendens. Översättning av Tom Sköld. Fri tanke förlag, 2019.

Chapter 1 What's Cheyenne Autumn by Mari Sandoz"Cheyenne Autumn" is a historical novel by Mari Sandoz, published in 1953. The book recounts the Cheyenne tribe's harrowing journey in 1878, as they attempted to return to their homeland in Wyoming after being forcibly relocated to reservations in Oklahoma. Through rich, evocative prose, Sandoz explores the themes of displacement, resilience, and the struggle for identity amidst the overwhelming forces of American expansionism.The narrative highlights key figures such as Chief Dull Knife and the challenges faced by the Cheyenne, including hunger, illness, and the brutal realities of life on the plains. Sandoz's empathetic portrayal gives voice to the Cheyenne people, shedding light on their culture, traditions, and the deep impact of colonization. The novel serves as both a poignant historical account and a reflection on the enduring spirit of a proud people.Chapter 2 Cheyenne Autumn by Mari Sandoz Summary"Cheyenne Autumn" by Mari Sandoz is a historical novel that vividly recounts the experiences of the Cheyenne people during the 1870s, focusing on their struggles and resilience in the face of westward expansion and U.S. government policies. The narrative primarily follows the Cheyenne tribe, particularly highlighting the journey and hardships faced by a group of Cheyenne led by a chief named Little Wolf as they seek to return to their homeland after being relocated to a barren reservation in Oklahoma. Central to the story is the theme of survival and the deep connection the Cheyenne have to their land, culture, and identity. The characters are depicted with depth, showcasing their traditions, spirituality, and the bonds of community amidst the suffering caused by violence, starvation, and broken treaties.The novel also explores the conflict between the U.S. government and Native American tribes, illustrating the injustices perpetrated against the Cheyenne. As the story unfolds, readers experience the courage and determination of the Cheyenne as they undertake the perilous journey northward, battling not just the elements but also their own disillusionment and trauma.Through rich descriptions and a blend of historical fact and fiction, Sandoz emphasizes the plight of the Cheyenne and other Native American tribes, making the narrative a powerful commentary on the impact of colonization and the importance of cultural preservation.Chapter 3 Cheyenne Autumn AuthorMari Sandoz was an American author born on May 11, 1896, in Warren, Nebraska, and she passed away on March 10, 1966. She is best known for her works that capture the history and experiences of the Great Plains, particularly in relation to Native Americans and early settlers. Cheyenne AutumnSandoz released Cheyenne Autumn in 1953. This historical novel focuses on the Cheyenne people's struggles and the forced relocation they faced, depicting both the Cheyenne and the American government's perspectives. It stands as a notable commentary on the injustices faced by Native Americans and reflects Sandoz's commitment to understanding and portraying their culture. Other Notable WorksMari Sandoz wrote several other books, including:Son of the Gamblin' Man (1945)Old Jules (1935) This semi-autobiographical work about her father is one of her most acclaimed books.The Battle of the Rosebud (1944) A historical novel about the battle involving Crazy Horse.The Cattlemen: From the Rio Grande to Montana (1941) A comprehensive account of the cattle ranching industry.The Horse and the Plains Indians (1955) A notable work highlighting the relationship between Native Americans and horses. Best EditionDetermining the "best" edition can vary based on personal preference—some readers prefer the original texts for their authenticity, while others prefer updated editions with additional...

Quels sont les progrès les plus marquants dans le diagnostic et le traitement des spondyloarthrites ? Quelles perspectives de recherche prometteuses pourraient transformer la prise en charge des spondyloarthrites ? Comment ces avancées et perspectives impactent-elles la pratique clinique et la qualité de vie des patients ?   Le Professeur Daniel Wendling, rhumatologue au CHU de Besançon, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêts avec AbbVie, BMS, MSD, Pfizer, Amgen, Nordic Pharma, UCB, Novartis, Janssen, Celgene, Lilly, Sandoz, et Alfa Sigma.   L'équipe :   Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud-Listrat, Dr Céline Vidal, Dr Sophie Hecquet Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer  

Redefining Sales Outreach with Gifting In this episode, Kris Rudeegraap explains how Sendoso uses AI and data to personalize gifting and revolutionize customer engagement. From streamlining logistics to automating gifting actions, Sandoz empowers teams to stand out in sales. Explore tips for leveraging gifting at every touchpoint to drive results and foster lasting connections

Today's episode delves into rehumanizing work within organizations, featuring our esteemed guest Frank Kellenberg, the Global Head of Culture and Inclusion at Sandoz. With over 20 years of leadership experience in international HR roles for companies like Hewlett Packard, Siemens, and Adidas, Frank brings a wealth of knowledge on leadership development, talent management, and the critical role of diversity, equity, and inclusion (DEI) in fostering a thriving company culture.In this episode, Frank shares:His perspectives on the importance of human connections in a technology-driven workplaceThe necessity of open and authentic communication from leadersThe challenges of adapting to different cultural environmentsHow Sandoz, a global leader in generic and biosimilar medicines, is navigating its cultural transformation post-independence from NovartisThe human leadership model, emphasizing trust, self-determination, and growthStrategies for implementing effective leadership training programs.We also touch on the future of work and the essential skills of empathy and communication in an increasingly automated world. Join us as we uncover practical insights to help leaders build human-centric workplaces where every employee feels valued and connected.Frank Kellenberg has more than 20 years of leadership experience in various operational and strategic HR roles in international companies, including Hewlett Packard, Siemens, Ingram Micro, adidas, and Novartis.Having worked for global organizations across Europe, Frank Kellenberg built his experience in culture, D&I, leadership development, talent management and organization development. He has a passion to drive innovation & change to help people & organizations to transform themselves to achieve goals. At the same time, he combines strategic and people-oriented thinking with a focus on operational excellence.Frank has an MBA in Business Psychology and also holds a Master's Degree in Adult Education.Connect with Andy Storch here:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Connect with Frank Kellenberg:LinkedInWebsite

Anna Tiomina has faced multiple FP&A challenges in a 15-year finance career. This has included budget nightmares, all-nighters, and the  stark realization that “politics” is central to any FP&A or finance role. The former CFO of Sandoz, a huge pharmaceutical company,  describes her move to finance chief at Softeq, a smaller IT and consulting firm. Most recently she has pivoted to become a fractional CFO with a passion to help finance professionals bridge the gap between “curiosity and confident AI adoption”. In this honest and frank interview, Anna describes The challenges for anyone  in a full time finance role when you don't have enough time to look at new things Structuring FP&A in a big company vs a smaller one Comparing and contrasting FP&A at a large and big companies Budget war stories When your key accounting person… is not an accountant  Ensuring a higher level of agility in budgeting Using AI in a safe way in FP&A Connect with Anna at: https://www.linkedin.com/in/anna-tiomina/ https://blend2balance.com/ Subscribe to her insights at: https://balancedai-newsletter.beehiiv.com/subscribe

Das schöne Herbstwetter lockt Menschen in ihrer Freizeit weiterhin an das Rheinufer. Die Stadtreinigung hat dort die Abfallcontainer allerdings schon abgeräumt, um sie an der Herbstmesse aufzustellen. Dass so viele bereits abgeräumt wurden, sei ein Fehler gewesen, heisst es auf Anfrage. Ausserdem: * Sandoz-Konzernchef zu der Idee der SP, dass der Bund die Sandoz kaufen soll: "Ich fühle mich geschmeichelt" * Die Post schliesst in den beiden Basel 6 Postfilialen.

Die SP will so sicherstellen, dass die Schweiz mit genügend Medikamenten versorgt ist. Beim Basler Wirtschaftsdirektor Kaspar Sutter kommt diese Idee nicht gut an. Die Risiken seien zu gross. Basta-Politiker Oliver Bolliger hingegen freut sich - seine Partei hatte bereits die gleiche Idee.  Ausserdem: * Im Baselbiet soll neu der Kanton und nicht mehr die Gemeinden darüber entscheiden, wo Fahrende einen Stellplatz erhalten * Studie zeigt: Die MCH bringt dem Kanton eine Wertschöpfung von 200 Millionen Franken * Abgespeckter ESC: Das wären die Folgen, wenn das Referendum in Basel angenommen wird

Am 24. November stimmt die Schweiz über den Ausbau der Nationalstrassen und somit auch über den Rheintunnel ab. Der Plan des Bundes: Der neue Tunnel soll die Osttangente entlasten. Einige Verkehrsexperten sagen nun, der Bund überschätze die Wirksamkeit der Rheintunnels.  Ausserdem: * SP Schweiz fordert die Verstaatlichung von Sandoz

Norman Ohler, author of 'Tripped: Nazi Germany, the CIA, and the Dawn of the Psychedelic Age', discusses the history of drugs in Nazi Germany and the CIA's involvement with LSD. He shares his personal interest in drugs and the different types of drugs, as well as the cultural differences between Germany and the US. Ohler also talks about his father's use of LSD to help his mother with Alzheimer's and the legal issues they faced. The conversation delves into the CIA's experimentation with LSD and the manipulation of individuals, as well as Ohler's research process and the challenges of accessing archives. The conversation explores the discovery of LSD and its potential as a medicine, as well as the political and societal implications surrounding its use. It delves into the history of LSD, including its connection to Nazi Germany and the CIA. The discussion highlights the need for more research and understanding of psychedelics, and the potential benefits they may have in treating mental health conditions. The conversation also touches on the importance of set and setting when taking psychedelics, and the need for responsible use. Show Links  Get 1-month of FREE access to the ⁠Vet Collective Community⁠ by using discount code: NLT1UQTI  Join us here: ⁠⁠⁠https://www.collective.vet⁠⁠⁠   Episodes also available on Spotify, Apple, and Amazon Music.  https://linktr.ee/harder_not_smarterNorman's Linkshttps://www.normanohler.deChapters 00:00 Introduction and Background of the Guest 01:48 Drug Use in Nazi Germany and the Third Reich 06:38 Cultural Attitudes Towards Drugs in Germany and the US 09:36 LSD as a Medicine and its Potential Benefits 13:04 Legal Issues and Personal Use of LSD 16:16 The CIA's Experimentation with LSD and Manipulation 23:54 The Discovery of LSD and Its Potential as a Medicine 26:02 LSD's Connection to Nazi Germany and the CIA 29:05 The Need for More Research and Understanding of Psychedelics 31:19 The Importance of Set and Setting in Psychedelic Experiences 37:22 Responsible Use of Psychedelics Takeaways Drugs have always been a part of human history and society, and it is important to understand their effects and potential benefits. The cultural attitudes towards drugs differ between Germany and the US, with Germany being more conservative and less informed about psychedelics. LSD was initially developed as a medicine by a Swiss pharmaceutical company, and its potential therapeutic uses are still being explored. The CIA's involvement with LSD was driven by the fear of its use as a truth serum and the desire to manipulate individuals. Accessing archives and original sources is crucial for accurate historical research, but it can be challenging to find specific information. LSD was discovered by Albert Hoffman and initially developed by the pharmaceutical company Sandoz as a potential stimulant for the mind. The discovery of LSD led to research on its potential therapeutic benefits, including its use in treating depression and other mental health conditions. The political and societal climate of the time, including Nazi Germany and the Cold War, influenced the perception and regulation of LSD. There is a need for more research and understanding of psychedelics, including their potential benefits and risks, in order to make informed decisions about their use. Set and setting, as well as responsible use, are important factors to consider when taking psychedelics.

Im Kanton Baselland wird der Platz für Asylsuchende knapp. Die Regierung muss deshalb die kantonalen Asylzentren ausbauen und länger in Betrieb halten als geplant, weil die Gemeinden zu wenig Asylsuchende aufnehmen können. * Nach mehr als 20 Jahren: Fussgänger-Passarelle vom Dreispitz zu den Merian Gärten ist in Planung * Archivserie: Fusion Sandoz und Ciba-Geigy zu Novartis (1996) Weitere Themen: - Archivserie: Pharma-Fusion Ciba-Geigy und Sandoz werden Novartis

Die Gmeinde Muttenz plant eine neue Vorschrift und will das Spucken in der Öffentlichkeit verbieten. Sie ist nicht die erste Gemeinde in der Region, die Spuckerinnen und Spucker büssen will.  Ausserdem: * In unserer Archivserie werfen wir einen Blick zurück auf die Fusion zwischen der Ciba und der Sandoz

Are you interested in digital health? Corporate innovation? Or even the future of healthcare?If you answered yes to any of those questions, this episode is for you. We sat down with Dan, Head of Innovation & New Commercial Partnerships at Sandoz Innovation Lab in Germany, to discuss how Sandoz is pioneering new approaches in patient care through digital health solutions and innovative partnerships.Dan's journey from molecular biotechnology to leading cutting-edge digital initiatives will show you how traditional pharmaceutical companies are embracing technology to push boundaries and improve healthcare.What we have discussed?– How Sandoz, a generic pharmaceutical company, drives innovation beyond products. – How they launched the first-ever biosimilar and how they continue to lead with 10 marketed molecules and 24 in development.– The current status, ePrescriptions, and the future potential of electronic patient records.– How curiosity, purpose, and collaboration foster "outside-the-box" ideas within the Sandoz Innovation Lab.– The partnership with Careanimation and its impact on improving health literacy and medication compliance with Apoclip.– Why market adoption can be slow and how smart risk-taking can accelerate the process.

Die Buchhandlung Vetter an der Spalenvorstadt hat einen Schwerpunkt im Bereich Religion. Nun ist nach 65 Jahren Schluss, per Ende Jahr schliesst die Buchhandlung. Es sei schwieriger geworden, Kunden für die religiöse Literatur zu finden. 38 Jahre nach Schweizerhalle: In der Archivserie hören wir, wie das Regionaljournal am 1.11.1986 über die Brandkatastrophe bei Sandoz berichtete und reden mit dem damaligen SRF-Redaktor.

Soll es im Kanton Basel-Stadt mehr Geld geben für Alternativkultur? Die sogenannte Musikvielfalts-Initiative fordert dies. In der Vergangenheit stellten sich linke Kreise meist geschlossen hinter ähnliche Anliegen. Bei dieser Initiative ist das nun aber anders. Ausserdem: Vor knapp 38 Jahren brannte in Schweizerhalle ein Chemikaliendepot der Sandoz. Der Rückblick in unserer Archivserie. Weitere Themen: - Archiv-Serie: Grossbrand von Schweizerhalle 1986

In dieser Episode spricht Georg Frey, Generalsekretär bei Sandoz, über die Ausgliederung von Geschäftsbereichen in eigenständige Unternehmen und welche Rolle der Generalsekretär dabei spielt. Zudem teilt er seine Erfahrungswerte bei der Umsetzung.The Agenda wird präsentiert von Sherpany, der führenden Schweizer Meeting-Management-Lösung.Thank you for listening! Visit us at Sherpany.com or follow us on LinkedIn for board, board committee, and executive meetings solutions.

Javier Cabedo es un tío que al que se le da genial 2 cosas: -Reflexionar sobre el antes y el después de las personas. -Dar visibilidad a sus propios proyectos. Si a esto le unimos su capacidad de liderar, entenderás mejor su papel como co-fundador de "News To You". La última década para él se resume en tres conceptos: madurez, aprendizaje y la búsqueda de la felicidad. Una prueba de ello son sus logros en el desarrollo de "News To You", una plataforma de medios de comunicación que revoluciona la forma en que consumimos noticias. Es de los que le encanta desafiarse a sí mismo, como lo demuestra su paso por diferentes roles en comunicación y transformación digital en empresas como Sandoz. Esto es solo una parte de lo que te puedes llevar de nuestra charla: - Sabrás la principal clave que permite a Javier grabar infinidad de episodios de su podcast y no desistir. - La explicación de por qué para Javier la humildad es crucial en su camino hacia el éxito. - La estrategia que ha usado para empezar a liderar proyectos y ganar autoridad en un sector tan complejo como la comunicación. —-------- 👉Creo estrategias para empresas y marcas que quieren comunicar a través de un podcast: https://jesusperezsantiago.com/ 👍 Dale a seguir en mi perfil ➕ Entrevisto a gente influyente en el mundo de la creación de contenidos y del podcasting para que sepas cómo han creado sus audiencias y generado negocio con ellas

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Clinical trials often fail to meet their enrollment goals and schedules, leading to significant financial losses. A new playbook offers solutions to address common challenges in clinical trial recruitment, including strategies for identifying additional participants, engaging and empowering individuals, and refining protocol criteria. The playbook provides insights on how to rescue trials when misalignment occurs, aiming to help brands in the biopharma industry tell compelling stories, build trust, and drive demand.Penumbra has decided to exit the virtual reality business, resulting in the layoff of 71 employees, as the company shifts its focus back to its core thrombectomy business. Qiagen and AstraZeneca have expanded their companion diagnostic partnership beyond cancer, allowing specialty care providers to perform genotyping during routine clinical examinations. Illumina has received FDA approval for a companion diagnostic cancer test that can identify patients eligible for treatment with specific medications targeting genetic features. Johns Hopkins, CareFirst, and Techstars have launched a healthcare AI accelerator program to support up to 12 startups working on AI tools. Medical sales teams are increasingly investing in training and skills development to adopt a more human-centered approach to sales.Biopharmaceutical company BioMarin has announced its second round of layoffs this year, with 225 employees globally being let go. This comes after changes to the company's C-suite last week and a previous round of 170 job cuts in May. In other news, Novartis is expanding its Sirna therapy Leqvio after successful Phase III study results, while Merck has ended two late-stage studies of Keytruda due to disappointing data. Regeneron is suing Sandoz in federal court to block a biosimilar of its drug Eylea. The pharma industry continues to see changes and challenges, with companies making strategic decisions based on clinical trial results and market conditions.Cognition Therapeutics, a small biotech company, recently announced positive results from a mid-stage Alzheimer's study. However, despite the promising results, the company's share price plummeted, puzzling many. The conflicting narratives surrounding the study highlight the significance of presenting scientific results in a way that reassures investors about the risks involved. The success of clinical trials is crucial for small biotechs in the competitive field of Alzheimer's research. Investor support is essential for advancing treatments for Alzheimer's, as progress cannot be made without adequate funding.The Health and Human Services (HHS) plans to appeal a lawsuit decision regarding online tracking technology. The Northwell-Nuvance merger has been approved by state attorneys general with certain conditions, while McLaren Health Care has restored its network after a ransomware attack. The shortage of mental health providers is being addressed with digital tools, and efforts to combat burnout in healthcare are ongoing.Neurocrine's mixed schizophrenia data disappoint Wall Street despite "positive" results, leading to a 20% slide in shares. The FDA rejection of the first MDMA therapy signals challenges in the psychedelic drug field. Bayer partners with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. A study suggests that covering Wegovy for heart risk could cost Medicare tens of billions each year.Pfizer has partnered with Flagship's Quotient to utilize genetics in targeting heart and kidney diseases. Moderna is facing tough competition as it tries to determine its next move in the biopharmaceutical industry. Neurocrine Biosciences saw a drop in shares despite meeting the primary endpoint in a mid-stage schizophrenia trial.Lykos Therapeutics faced a setback when the FDA rejected its MDMA therapy for PTSD and laun

On today's episode of The Coffee Break, Russ spoke with Priscilla and Amy about the upcoming Beef, Beans & Bluegrass Festival taking place August 23-25th.  The Coffee Break is the daily Christian talk and local events program on Hope Radio KCMI 97.1FM serving the Scottsbluff, NE area. Tune in for interviews with authors, musicians, pastors, and others in the Christian community and our local area! Visit our website: www.kcmifm.com Like us on Facebook: www.facebook.com/kcmifm

Cet été, retrouvez dans Home(icides) les plus grandes affaires criminelles françaises. De la disparition de Xavier Dupont de Ligonnès, à la secte du Temple solaire, en passant par l'affaire Grégory... elles ont marqué et marquent encore la société, même des années après. Caroline Nogueras vous plonge au cœur d'enquêtes complexes, de procès hors-norme et de familles déchirées. (Re)découvrez l'histoire d'une communauté secrète en plein Paris : La Famille, un récit d'emprise familial. Mon oncle Auguste La famille se réunit autour d'une chrétienté en marge de l'Eglise, régi par l'austérité et la discrétion. Depuis sa création en 1819, d'autres patronymes sont venus grossir les rangs. Les Havet et Thibout ont été rejoints par les Sanglier, Déchelette, Sandoz, Maître, Pulin et Fert. Au début du XXeme siècle, un homme, Paul Augustin Thibout, descendant direct des fondateurs, va durcir le ton et cadrer les troupes. Production et diffusion : Bababam Originals Un podcast enregistré dans les studios de Bababam Ecriture : Capucine Lebot Voix : Caroline Nogueras Suivez Bababam sur Instagram. Première diffusion : 2 octobre 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Astellas Pharma, Inc. v. Sandoz Inc.

This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron fist is the best way to get results in the pharmaceutical industry.  In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gained over the course of her career and the importance of valuing your people and being valued in return.  A little more on EMJ GOLD's guest… Claire D'Abreu-Hayling is the Chief Scientific Officer at Sandoz, and with more than 30 years of experience in the pharmaceutical industry under her belt, she knows a thing or two about life sciences leadership - past and present. At the company Claire oversees the global product development network where she manages infrastructure strategy, pipeline execution and talent acquisition for both small molecules and biosimilars. Outside of work, Claire is a true champion of authenticity in the workplace. She is passionate about diversity, equity and inclusion and is particularly committed to mentoring Black and Asian women who are pursuing careers in STEM.

Generics Bulletin's editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA's Orange Book.

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

Tripped: Nazi Germany, the CIA, and the Dawn of the Psychedelic Age by Norman Ohler https://amzn.to/3PWxLlE The author of the New York Times bestseller Blitzed returns with a provocative new history of drugs and postwar America, examining the untold story of how Nazi experiments into psychedelics covertly influenced CIA research and secretly shaped the War on Drugs. Berlin 1945. Following the fall of the Third Reich, drug use—long kept under control by the Nazis' strict anti-drug laws—is rampant throughout the city. Split into four sectors, Berlin's drug policies are being enforced under the individual jurisdictions of each allied power—the Soviet Union, Britain, France, and the US. In the American zone, Arthur J. Giuliani of the nascent Federal Bureau of Narcotics is tasked with learning about the Nazis' anti-drug laws and bringing home anything that might prove “useful” to the United States. Five years later, Harvard professor Dr. Henry Beecher began work with the US government to uncover the research behind the Nazis psychedelics program. Begun as an attempt to find a “truth serum” and experiment with mind control, the Nazi study initially involved mescaline, but quickly expanded to include LSD. Originally created for medical purposes by Swiss pharmaceutical Sandoz, the Nazis coopted the drug for their mind control military research—research that, following the war, the US was desperate to acquire. This research birthed MKUltra, the CIA's notorious brainwashing and psychological torture program during the 1950s and 1960s, and ultimately shaped US drug policy regarding psychedelics for over half a century. Based on extensive archival research on both sides of the Atlantic, Tripped is a wild, unconventional postwar history, a spiritual sequel to Norman Ohler's New York Times bestseller Blitzed. Revealing the close relationship and hidden connections between the Nazis and the early days of drugs in America, Ohler shares how this secret history held back therapeutic research of psychedelic drugs for decades and eventually became part of the foundation of America's War on Drugs.About the author Norman Ohler is an award-winning German novelist, screenwriter, and journalist. He spent five years researching Blitzed in numerous archives in Germany and the United States, and spoke to eye-witnesses, military historians, and doctors. He is also the author of the novels Die Quotenmaschine (the world's first hypertext novel), Mitte and Stadt des Goldes (translated into English as Ponte City). He was co-writer of the script for Wim Wenders' film Palermo Shooting.

In TRIPPED, his intriguing new history of drugs and postwar America, the German writer Norman Ohler makes LSD both a symbol and a metaphor for the history of the Cold War. Linking Nazi Germany, the CIA with what he calls “the dawn” of the psychedelic age, Ohler presents LSD — the revolutionary psychedelic drug invented by the Swiss pharma giant Sandoz which the Nazi tested as a “truth serum” in Dachau — as a weapon used by the American military-industrial complex to fight the Soviets. As with most anti Soviet CIA plots, of course, it was a bit of a farce - although Ohler's thesis certainly offers an alternative way of interpreting trippy Cold War movies like Doctor Strangelove and The Manchurian Candidate. And Ohler reminds us of the psychedelic age's most lasting legacy - its influence on West Coast countercultural figures like Ken Kesey, Stewart Brand and Steve Jobs and their invention of the personal computer and internet.Norman Ohler is an award-winning novelist, screenwriter, and journalist. He is the author of the New York Times bestseller Blitzed, the non-fiction book The Bohemians about resistance against Hitler in Berlin, as well as the novels Die Quotenmaschine (the world's first hypertext novel), Mitte, Stadt des Goldes (translated into English as Ponte City), as well as the historical crime novel Die Gleichung des Lebens. He was cowriter of the script for Wim Wenders's film Palermo Shooting. He lives in Berlin.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über den Absturz der Trump-Aktie, KI-Fantasie bei Micron und fragwürdige Reddit-Moves. Außerdem geht es um Tesla, Nvidia, Mondelez, Netflix, Wendy's, Janus Henderson, MSG Sports, 3M, Solventis, GE Aerospace, GE Vernova, GE Healthcare, Sandoz, Novartis, WK Kellog, Kellog, Veralto, Danaher, Crane und Keynote Spin-Off Fund (WKN: A2PBAA). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Biotech veteran Art Krieg has postponed his retirement to start a new drug startup called Zola Therapeutics, focusing on cancer immunotherapies without outside investors. Stoke's shares surged on updated results for their drug for Dravet syndrome, a form of genetic epilepsy. Moderna received backing from Blackstone for flu vaccine research and development. Armon Sharei, founder of the now-liquidated SQZ Biotechnologies, is starting over in biotech with a focus on cell therapies. The newsletter Gene Therapy Weekly provides insights into the latest news and trends in the biopharma industry, covering topics such as clinical trials, FDA approvals, gene therapy, and more. Industry Dive's Biopharma Dive publication offers in-depth journalism and analysis for decision makers in the biotech and pharma sectors.CVS has entered the biosimilar drug market with a new venture, as more than three dozen biosimilars have been approved in the U.S. However, their impact has been limited by patent thickets and insurance contracting that favors brand-name drugs. Despite this, there are signs that biosimilars are gaining momentum. Other stories in the biosimilars market include biosimilar makers adopting different strategies to compete with top-selling drugs like Humira, and Sandoz spinning out of Novartis to become a standalone generic drugmaker. This trendline provides insights into the state of the biosimilars market and is independently produced by journalists. Sponsorship opportunities are available for those interested in reaching biopharma industry executives. Biopharma Dive is a product of Industry Dive, Inc. located in Washington, DC.Walgreens has experienced a $6 billion loss due to the depreciation of the value of VillageMD, resulting in the closure of 140 VillageMD locations. CMS has implemented new regulations to streamline Medicaid and CHIP enrollment processes. UCI Health has completed a $975 million purchase of four Tenet hospitals, while Ascension is divesting three hospitals in northern Michigan. Additionally, over 2,000 nurses are planning to strike in Santa Clara County. Healthcare organizations are facing challenges related to staffing shortages, and technology is being recommended as a solution. UnitedHealth is offering loans to providers affected by cyber attacks, and efforts are being made to keep 'site neutral' policies alive. University of Michigan Health workers have unionized. Healthcare Dive provides insights on various topics including health IT, policy and regulation, insurance, digital health, and value-based care.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Astrazeneca acquired a biotech startup called Amolyt for $800 million, adding a late-stage drug prospect for parathyroidism to its rare disease portfolio. Bio, a lobbying group for the biopharmaceutical industry, changed its stance and now supports a bill to limit China's role in US biotech. German biotech Tubulis secured €128 million in financing to capitalize on the momentum in antibody-drug conjugates (ADCs). J&J and Novo are supporting Asgard's efforts to develop personalized cancer therapies that reprogram tumor cells in the body. The FDA is focusing on early deaths in a meeting regarding broader CAR-T use in myeloma, particularly in trials from Bristol Myers Squibb and Johnson & Johnson. Additionally, there are five questions facing emerging biotech companies as they navigate through the industry's current landscape. The newsletter also covers various topics including the use of AI-enabled digital twins to secure the pharmaceutical supply chain, Medicare coverage of weight-loss drugs, and shifts in the clinical trial landscape.The EPA has issued a final rule limiting ethylene oxide emissions from medical device sterilizers, giving companies two years to comply. Exactech received a warning letter from the FDA regarding faulty implant packaging analysis. US hospitals expect an increase in procedures as staffing pressures ease, potentially benefiting companies like Boston Scientific, Medtronic, and Stryker. The FDA is seeking feedback on expanding premarket cybersecurity guidance. Additionally, AI and digital health trends are becoming more prominent in the medical device industry.AstraZeneca has acquired Amolyt Pharma for $1.05 billion, adding to its rare disease portfolio with late-stage candidate eneboparatide for hypoparathyroidism. The deal also includes ownership of azp-3813, being assessed for acromegaly in a phase I trial. In other news, Vertex failed to convince the UK watchdog of the value of its CRISPR therapy Casgevy, and Wuxi AppTec has been removed from a trade group amid US national security concerns. ADC Biotech Tubulis closed a $138 million financing round to support its lead solid tumor antibody-drug conjugate candidates.The Biden administration has proposed the implementation of "march-in rights" to seize patents for drugs that are priced unreasonably high. This move has sparked debate among stakeholders, with concerns about the potential negative impact on innovation in drug development. Despite efforts to bring down drug prices, critics believe that federal intervention in patent protection could have devastating consequences.The biosimilars market in the U.S. has been limited by patent thickets and insurance contracting, but there are signs of momentum. CVS has launched a new venture in biosimilar drug experimentation, while biosimilar makers are using different strategies to compete with top-selling drugs like Humira. Sandoz has spun out of Novartis to become a standalone generic drugmaker.Thank you for listening to Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Several developments in the biopharma industry were reported on March 6. Gilead made a bet on 'trispecifics' in a new cancer drug deal, Alumis secured $259 million for its work on a drug targeting Tyk2, Regenxbio's data showed promise in Duchenne gene therapy, Alnylam and Roche's blood pressure drug performed well in a mid-stage trial, and Sionna raised $182 million to challenge Vertex in cystic fibrosis treatment. The sector saw a surge in biotech IPOs at the beginning of 2024, prompting discussions on whether this trend will continue. The biosimilars market in the US has been growing steadily since its slow start in 2015. Additionally, Brazil declared a state of emergency due to dengue cases, AstraZeneca invested in the UK for pandemic preparedness, and companies rushed to preserve skeletal muscle after the success of obesity drugs.Dexcom has received FDA approval for the first over-the-counter continuous glucose monitor for people with type 2 diabetes. Vicarious continues to focus on launching its soft tissue robot despite financial struggles. Smiths Medical has recalled nearly 86,000 syringe pumps due to a software issue. Haemonetics is set to acquire Attune Medical for $160 million. Medtronic estimates up to 40 job losses in Ireland as part of restructuring efforts. The EU Medical Device Regulation is causing challenges for small and medium-sized medtech companies. Other news includes Philips being sued for milestone payments, a dentistry AI developer receiving a $53 million investment, and CMS rolling out provider flexibilities amid cyberattack fallout.Alumis has raised $259 million in a Series C funding round, making it the largest haul in 2024 for a private biotech company. The California-based biotech plans to use the funding to move its tyk2 inhibitor into phase III for plaque psoriasis, potentially challenging competitors Bristol Myers Squibb and Takeda in the autoimmune market. Other key focuses for investors in 2024 include psychedelics and solid tumors. Sandoz has received FDA approvals for the first two biosimilars for Amgen's denosumab, while Sionna Therapeutics has closed a $182 million Series C round to potentially challenge Vertex Pharmaceuticals in the cystic fibrosis market. Overall, experts anticipate increased interest in the autoimmune and obesity spaces this year, following a trend of heightened investment in oncology and neuroscience in 2023.In 2024, investors are expected to focus on psychedelics, solid tumors, autoimmune, and obesity drugs in the biopharma industry. Pfizer's decision to prioritize biologics over small molecules was influenced by the Inflation Reduction Act (IRA). Researchers suggest that the IRA could potentially discourage drug developers from pursuing subsequent indications for existing drugs, leading to a decrease in new drug approvals. Biopharma mergers and acquisitions are on the rise, with Biospace launching an M&A tracker to keep track of industry transactions. The 10th Annual American Biomanufacturing Summit is set to bring together industry leaders to discuss current trends and best practices. In other news, AstraZeneca lost a court case related to the IRA, the ADC market in oncology is expected to reach $30 billion by 2028, and various biopharma companies have secured substantial funding for drug development. Pfizer is focusing on four main cancer types and aims to launch eight blockbuster drugs by 2030.

Matthew King is an Entrepreneurial Investor passionate about venture investing & building, deeptech, sustainability, mental health, wellness, automotive, luxury goods, and hospitality.Currently Co-Founder & Managing Partner at Valhalla Ventures, a venture capital firm backing visionary founders at the forefront of social and technological breakthroughs.Inveterate connector of extraordinary human beings who frequently colors outside the lines and thrives on helping founders accomplish legendary outcomes while helping investors produce stellar returns & impact.Valhalla Ventures backs visionaries building enduring moats.Today, the most enduring moats exist in physical technology (think industrials, space, chips, biology, defense, energy, etc) and media IP (think games).Valhalla manages $200M+ in assets with $150M in committed capital across all vehicles to date. Our primary focus currently is deploying $35M in dry powder in Seed and Series A financings (and in between), investing $1M to $3M per company with a 5% minimum ownership target. Valhalla's Limited Partner community includes:1) C-suites/Managing Partners (current and former) of: Goldman Sachs, JP Morgan Chase, Bank of America, Citadel, Bridgewater Associates, Oaktree Capital, Apollo Global, Point72, PayPal, Alibaba, Hillhouse Capital, NBC Universal, General Motors, Swiss Re, Discover, PizzaHut, DoorDash, DocuSign, Sandoz, Gusto, Guinness, Bitmain, Thomson Reuters, Yahoo, Zynga, the Dallas Cowboys, BlockTower Capital, and TopGolf; and2) Board Members (current and former) of: BlackRock, Goldman Sachs, MasterCard, MIO Partners, Fortress, BNY Mellon, RBC, Altria, ARM Semiconductor, SoFi, Warburg Pincus, Kraft, SABMiller, Cognizant, Western Union, Raine Group, Harvard Business School, Harvard Law School, Harvard Medical School, Harvard University, Stanford's Graduate School of Business, Wharton, and Johns Hopkins University.Outside of work what energizes me is travel (40+ countries visited or lived in), electronic music, nature, and Burning Man (12x). --- Support this podcast: https://podcasters.spotify.com/pod/show/geeksofthevalley/support

Support Lorenzo on Patreon.com Guest speaker: John Beresford PROGRAM NOTES: Dr. John Bereford delivering this talk in 2006 at the conference celebrating Albert Hofmann's 100th birthday. Today's program features a lecture by psychedelic researcher Dr. John Beresford. Here is Erowid's introduction to him: "British-born John Beresford began his psychedelic research interests in 1961, and shortly thereafter he resigned his post as an Assistant Professor of Pediatrics at New York Medical College. In 1963 he founded the Agora Scientific Trust, the world's first research organization devoted to investigating the effects of LSD. In contrast to Leary's invitation to "tune in, turn on, and drop out", Beresford initially wanted to keep LSD as a tool of scientifically trained specialists. However, later in his life he adopted a viewpoint that was opposed to the medicalization of psychedelics." Of course, the story that he is best known for is the time that he wrote to Sandoz Laboratories and requested one gram of LSD! (If my math is correct, that's about 4,000 doses of 250 mics each.) Amazingly, Sandoz sent him a gram through the mail and attached a note that read, "Good luck." The talk we are about to listen to was given by Dr. Beresford at the conference celebrating Albert Hofmann's 100th birthday. He titled it: "Psychedelic Agents and the Structure of Consciousness: Stages in a Session Using LSD and DMT".

George Glynos, head of research at ETM Analytics gave an update on the two-pot retired system.      Sean Capazorio, group chief financial officer at Aspen Pharmacare on it concluding two significant agreements with Sandoz for China and Europe.   Justice Mukheli, multidisciplinary artist discussed how he makes his money through his various career disciplines.See omnystudio.com/listener for privacy information.

With increasing release of biosimilars, listen to this discussion about use, fear of change, dual pricing strategies and who will see cost savings with Jason Harris, NPF VP of Government Relations and Advocacy, dermatologist and past chair of the NPF Board Dr. Colby Evans, and Anna Hyde, VP of the Advocacy and Access Department at the Arthritis Foundation. This Psound Bytes episode is sponsored by Sandoz and Boehringer Ingelheim. 

Il y a 80 ans, le chimiste Albert Hofmann enfourchait son vélo pour une folle cavalcade à travers Bâle, imprégné volontairement et surpris par la substance quʹil était parvenu à synthétiser quelques années plus tôt : le LSD. Il était alors loin de se douter que cette drogue psychédélique, capable de soulager certaines maladies psychiques, allait devenir, avec lʹaide dʹanciens chimistes nazis, un objet de recherche militaire et un outil de contrôle mental utilisé par la CIA pendant la Guerre froide. Loin également dʹimaginer que le LSD allait non pas déferler sur le marché du médicament grâce à sa firme Sandoz, mais accéder à la notoriété grâce au mouvement psychédélique et aux milieux artistiques et intellectuels des années 60. En 1966, il est interdit et retombe finalement dans la clandestinité. Aujourdʹhui la recherche montre un intérêt renouvelé pour le potentiel thérapeutique des substances psychédéliques comme le LSD. Daniele Zullino est psychiatre et médecin chef du service dʹaddictologie des Hôpitaux universitaires de Genève, il est au micro de Céline Roduit pour Histoire Vivante. Production : Anaïs Kien